Antag Pharmaceuticals

Antag Pharmaceuticals is a clinical-stage biotechnology company based in Copenhagen, Denmark, dedicated to developing first-in-class therapies for metabolic diseases. The company's primary focus is on the development of Glucose-dependent Insulinotropic Polypeptide (GIP) receptor antagonists, a novel approach to treating obesity and related metabolic disorders. Spun out from the University of Copenhagen, Antag leverages the world-leading expertise of its founders in GPCR pharmacology and the GIP system. Their lead candidate is currently being evaluated in clinical trials for its potential to reduce body weight and improve metabolic health. The company is supported by high-profile life science investors, including Novo Holdings and the Wellcome Trust.